top of page

A Creative Approach to Deal-Making for Small

and Mid-Sized Government Contractors

By Senior Managing Director, Robert Rubin

Current market conditions are having a profound impact on the value of small and mid-sized government contractors. The macro factors impacting the industry present major challenges to sustaining growth, maintaining profitability and enhancing enterprise value.

When forced to confront the reality of survival, a sale at currently depressed prices, though unappealing, may seem to be the only viable option available to produce any value for shareholders. However, is this the only option? We believe that there are other options for small and mid-sized government contractors (revenues up to $50 million) to not only survive, but thrive, and position themselves for a significant enhancement in shareholder value.

Though the fundamentals of government contracting may still be more attractive than many other sectors of the economy, continuing to do business the same way increases the risk of becoming marginalized and experiencing a potentially slow and possibly long decline.


The Forgotten M in M&A

Historically there has been a much greater volume of “A” acquisition than “M” merger activity. For purposes of this article, the term merger is being used in the strategic and business context. A discussion of some of the legal issues that arise will also be examined later in this article. Acquisitions tend to be more straightforward as the parties agree on a purchase price and terms and at the closing the buyer assumes authority over management, decision making and issues impacting the corporate culture. In contrast, a merger is a “union of two or more entities into one” – where integrating the operating and cultural needs of the parties into a workable environment becomes a more collaborative effort.

Resolving the most basic elements of a transaction, such as valuation and ownership control, can be significantly more difficult and time consuming in a merger. In spite of these additional complications, we are seeing increased activity in merger transactions for small and mid-sized government contractors as a practical response to current market conditions where valuations have experienced a significant decline.


Recent Merger Activity

Let’s look at a real life example to understand how a merger works.

ABC is a $50 million government contractor providing high end engineering services including simulation and training to customers throughout the Department of Defense (DoD). The majority of their business is in the intelligence community. Until recently, ABC experienced double digit revenue growth and profit margins. Beginning in 2016, however, as customer budgets declined, the movement toward larger contract awards and schedules and increased pressure to become a subcontractor, ABC experienced a significant slowdown in new business awards resulting in flat revenue growth and a 33% decline in profit margins. In the near term the Company implemented actions to stabilize profit margins by selectively reducing their fixed cost structure. To be able to compete for larger contract awards and return to historical levels of growth and profitability, senior management identified the need to achieve greater critical mass-- $100 million revenue. To reach this target in the next 3-5 years, will likely require a combination of organic growth supplemented by multiple strategic acquisitions. While ABC had excess cash and the availability of bank debt to complete these transactions, they were concerned that taking on the leverage necessary to complete these transactions could have a significant negative impact on their financial flexibility.


In their search, ABC met Company XYZ which had $10 million in revenues. Much of their business was concentrated in the intel space and most of their people had high level clearances. Both parties saw a strong business case as there was little overlap of customers and skills and identified opportunities to leverage a wider range of skills across a large customer base. Just as importantly, the senior management of both companies hit it off and shared many of the same basic beliefs and culture. In addition, there was little redundancy and opportunities to rationalize the back office. Owner of XYZ wanted to stay on for some time after a transaction.

Great chemistry, great business case, ABC did not want to take on the debt that was going to be required to complete this transaction—what to do? A transaction structured with some cash to seller at closing and the remainder of the purchase consideration of stock in ABC provided the seller with a nice amount of cash at closing and the incentive to continue to work hard for the combined entity.


What this created:

  • More critical mass—a 20% increase in revenues and increased level of profitability

  • Greater opportunity for the combined entity—identified numerous opportunities that they could not have gone after on their own

  • The opportunity to come up with a more competitive cost structure—while there were few headcount reductions, spreading ABC’s G&A and OH structure across a wider revenue base resulted in a more competitive cost structure. Immediately becoming more competitive

  • Expansion of management team to include owner of XYZ.

  • Articulation of common goals and exit strategy which reduces a lot of the risk associated with a transaction

  • The ability to complete the transaction without crippling the balance sheet with debt


Keys for Success

An important factor for success in a merger is the development of detailed strategic and operating plans which incorporate clearly identified and measurable financial goals and milestones, specific management responsibilities, and an agreed upon exit strategy. While the keys to a successful merger entail many of the same strategic considerations as an acquisition, other considerations which require serious examination include:

  • Compatibility of corporate cultures

  • Alignment of management structure and style

  • Agreement on long term shareholder goals and expectations

  • Initial valuation of both enterprises

  • Structuring of corporate governance

  • Mechanism for resolving major issues that arise

  • Agreement on exit horizon


The importance of these issues and the time required to reach agreement should not be minimized, and can be even more complicated where a private equity firm or financial owner is involved. If done correctly, however, the success of any transaction is greatly enhanced.

M&A the same old way? Not likely! With continued pressure on growth and profit margins, small and mid-sized government contractors are going to have to be more flexible and creative in accumulating the resources to realize their full potential. Companies and investors with the financial resources and fresh approaches to creating value will may be handsomely rewarded with transformational opportunities at prices not seen in the market for years.

Completing a merger requires a broad skill set to address the many challenges that a straight acquisition does not. The principles of Boustead Securities, LLC have the unique combination of M&A, financial and operational skills to accomplish these transactions.

If you would like to discuss how a merger or an acquisition can impact your company, please contact me at:


Robert Rubin

301.537.8221



 


About Robert N. Rubin

Robert Rubin joined Boustead as Senior Managing Director in 2020 and has over 35 years of experience in Mergers and Acquisitions, the last 25 of which have been specifically focused on the technical services marketplace including Aerospace, Defense and Government contracting in the Washington DC Metropolitan area. In addition to his background in M&A, he has extensive experience in corporate finance and development with public and privately held companies. He has been involved in more than 40 transactions worldwide, and served as President of the National Capital Chapter and on the International Board of Directors for ACG. Robert is a FINRA registered representative and holds series 7, 24, 63, 79 and 99 licenses. For more information on M&A's contact: Robert Rubin (301) 537-8221 Robert.Rubin@boustead1828.com


 

About Boustead Securities, LLC

Boustead Securities, LLC (“Boustead”) is an investment banking firm that executes and advises on IPOs, mergers and acquisitions, capital raises and restructuring assignments in a wide array of industries, geographies and transactions, for a broad client base. Boustead’s core value proposition is the ability to create opportunity through innovative solutions and tenacious execution. With experienced professionals in the United States, Boustead’s team moves quickly and provides a broad spectrum of sophisticated financial advice and services. Boustead is a majority owned subsidiary of Boustead & Company Limited, a diversified non-bank financial institution. For more information, please visit www.boustead1828.com.

Form CRS/Reg BI Disclaimer:

Boustead Securities, LLC is registered with the Securities and Exchange Commission (SEC) as a broker-dealer and is a member of the Financial Industry Regulatory Authority (FINRA) and the Securities Investor Protection Corporation (SIPC). Brokerage and investment advisory services and fees differ and it is important for you to understand these differences. Free and simple tools are available to research firms and financial professionals at Investor.gov/CRS, which also provides educational materials about broker-dealers, investment advisers, and investing. When we provide you with a recommendation, we have to act in your best interest and not put our interest ahead of yours. At the same time, the way we make money creates a conflict with your interests. Please strive to understand and ask us about these conflicts because they can affect the recommendations we provide you. There are many risks involved with investing. For Boustead Securities customers and clients, please see our Regulation Best Interest Relationship Guide on the Form CRS Reg BI page on our website at https://www.boustead1828.com/form-crs-reg-bi. For Sutter Securities’ and Sutter Securities Clearing’s customers and clients, please see the Form CRS on the website at https://suttersecurities.com/wp-content/uploads/2020/12/Sutter-Form-CRS-combined-121020.pdf. For FlashFunders’ visitors, you may review the Form CRS of Boustead Securities, Sutter Securities and Sutter Securities Clearing under the Form CRS section. Please also carefully review and verify the accuracy of the information you provide us on account applications, subscription documents and others.

Cautionary Statement Concerning Forward-Looking Statements

This document contains forward-looking statements. In addition, from time to time, we or our representatives may make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our growth in revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as “may,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential,” or “hopes” or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of the Company; our ability to keep pace with new technology and changing market needs; and the competitive environment of our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this document and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties and assumptions about us. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this document and other statements made from time to time by us or our representatives might not occur.

Transaction includes proprietary IP and technology for blood-based immune therapy monitoring and for transplant rejection testing.


Novel, patented copy number index (CNI) therapy monitoring test developed by Chronix complements Oncocyte’s proprietary DetermaIO™ test for immunotherapy treatment selection and may significantly expand the market opportunity for the Company.


Boustead Securities, LLC (“Boustead”) is pleased to announce that its client Chronix Biomedical, Inc., a privately held molecular diagnostics company developing blood tests for use in cancer treatment and organ transplants, has entered into an agreement to be acquired, through a subsidiary, by Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the cancer care continuum. Boustead invested in and serves as exclusive financial advisor to Chronix.


Under the agreement, which supersedes the previous collaboration agreement between the companies announced in October 2020, Oncocyte intends to acquire the intellectual property (IP) and technology for Chronix’s TheraSure™-CNI Monitor, a patented, blood-based test for immune-therapy monitoring, as well as the IP for Chronix’s organ transplant technology.


Dr. Ekke Schuetz, CEO and John DiPietro, CFO of Chronix stated "It was a pleasure to work with Boustead, and our banker Pete Conley was instrumental in advising us on the merger with OncoCyte. We appreciate all his efforts and his knowledge and experience in the biotech industry was extremely helpful.”


Chronix’s development and business team will likely become part of the Oncocyte R&D Team and intends to maintain lab operations in Germany to support the continued development and commercial launch of the monitoring tests. The EU-based team intends to also lead Oncocyte’s commercial efforts with DetermaRx™ and DetermaIO™ in Germany and other EU member countries upon closing of the transaction.


Cancer modifies the normal genome of cells by accumulating mutations and variation in the number of copies of genes in the genome. The proprietary CNI test developed by Chronix quantitatively measures the amount of that copy number variation (CNV) present in blood that has been shed by dying tumor cells.


Monitoring the change in CNI over time for patients on therapy allows a physician to monitor response or progression and adjust treatment accordingly. Oncocyte intends to accelerate further development of the CNI test, which is already supported by peer-reviewed publications, as the Company prepares to launch the test for research use and pharma trials in the second half of 2021. The initial focus will likely be on clinical studies in lung cancer and other solid tumor types treated by immunotherapy.


The Company believes the addition of the CNI test may enable it to enter into blood-based immune-therapy monitoring, which has an estimated Total Available Market of over $3 billion in the United States alone.


“Having worked very closely with Chronix over the past few months we gained greater insight into, and performed more analysis of, the overall potential of Chronix’s IP,” said Ron Andrews, Chief Executive Officer and President of Oncocyte. “After our evaluation, we believe that acquiring Chronix, whose technology includes 12 granted U.S. and EU patents across seven patent families, provides us with a strong patent portfolio that can serve as the basis for our blood-based therapy monitoring and recurrence monitoring programs, and ultimately create significant value for Oncocyte. The acquisition also establishes a footprint in the EU for our Company and access to an incredibly talented team with years of development experience in blood-based testing for cancer therapy and transplant rejection. We anticipate the first application of the CNI test to be for immune-therapy monitoring, which may add another component to our capabilities in the immunotherapy setting, providing a comprehensive solution when used along with DetermaIO™ immunotherapy response prediction. While we expect DetermaIO to play an incredibly important part in the immunotherapy diagnostic story, monitoring resistance to checkpoint inhibitors through the CNI test would fill a tremendous unmet need. With between 40%-60% of patients failing to see a sustained respond to immune checkpoint inhibitors, we estimate that by 2025, more than $60 billion a year could be misspent on treatments that may never benefit patients. Identifying these patients early may enable oncologists to make a timely change in therapy management, potentially improve patient outcomes, and provide significant savings in unnecessary health care costs. We look forward to integrating and working with the Chronix team to extend the patent estate which we believe will likely establish Oncocyte as a leader in the emerging targeted and immune therapy monitoring market. We expect this acquisition to create a strong competitive advantage in the market that may be beneficial to the medical community, payors and patients, as well as to our shareholders.”


A study published on the Chronix CNI test in Clinical Cancer Research, “Tumor Cell-Free DNA Copy Number Instability Predicts Therapeutic Response to Immunotherapy”, showed 92% predictive value for disease progression prior to cycle two of therapy (at 6 weeks) and close to 100% prediction prior to cycle three (9 weeks), including timely identification of hyper-progression which affects as much as 20% of lung cancer patients on immunotherapy. This data is indicative of the utility of Chronix’s patented CNI test as a blood-based test to identify tumor resistance to therapy significantly earlier than imaging alone and may serve an important role in assisting physicians treating cancer patients with knowledge that could lead to better patient outcomes.


Dr. Ekkehard Schuetz, CEO and Chief Medical Officer of Chronix said, “One of the key benefits of the TheraSure-CNI Monitor test is that it does not require tissue upfront. Obtaining biopsy tissue for testing can be very challenging in certain tumor types, particularly in lung cancer with 15-30% of patients not having enough tissue to complete molecular testing. Our publications demonstrate that detection of changes in CNV load is remarkably accurate in detecting disease progression on therapy. It is suitable for monitoring patients being treated with chemotherapy, targeted therapy or immunotherapy. With DetermaIO and the CNI Monitoring test, the combined company aims to provide a comprehensive solution that addresses two of the biggest challenges in the field of immune therapy: determining those who may best respond early in the patient management cycle, and monitoring for failure to respond and development of resistance. We had the great privilege of working closely with the Oncocyte team over the past few months and believe that together we have the opportunity to build upon the patent estate and further our footprint in therapy monitoring and cancer recurrence monitoring.”


Continuing, Mr. Andrews stated, “Gaining the Chronix technology moves us closer to our goal of establishing Oncocyte as the ’go-to’ choice for oncologists treating patients with immune therapy and for biopharma companies who need to select the appropriate patients for immunotherapy clinical trials. By offering the combination of DetermaIO and the CNI test, we believe we will become the only company with diagnostic tests that can identify patients for immunotherapy treatment and then also be able to monitor the patients’ responses to those treatments in real time, before tumor resistance can be seen in imaging, two integral components of patient management. Our next step is to conduct a definitive prospective study that will likely allow us to bring the CNI test to market, first in Germany and the EU, and eventually in the US once reimbursement is achieved. Once launched, we expect to drive significant market share advantage among oncologists in the US and EU.”


About the Proposed Merger and Principal Transaction Terms

Upon closing, Oncocyte intends to deliver closing consideration of $2.675 million in cash and $1.5 million of Oncocyte common stock (or approximately 295,000 shares) and will likely assume liabilities not to exceed $5.5 million. The agreement also provides for Oncocyte to pay a revenue share on the net collected revenues for certain tests and services for specific periods, and to pay a combination of cash or Oncocyte common stock of up to $14 million if certain milestones are achieved. The closing of the merger is subject to a number of conditions, including approval of the transaction by Chronix shareholders, and is expected to be completed by April 30, 2021. Oncocyte intends to deliver shares that may be sold following the closing pursuant to an effective Registration Statement. Additional information regarding the terms of the transaction will be provided in the Company’s Current Report on Form 8-K expected to be filed with the Securities and Exchange Commission on or about February 5, 2021.

Boustead acted as exclusive financial advisor to Chronix.


About Chronix Biomedical

Chronix Biomedical, Inc. is a privately held, U.S.-based molecular diagnostics company developing blood tests for use in cancer treatment and organ transplantation. Chronix’s TheraSure™ CNI Monitor for cancer uses proprietary algorithms to derive a copy number instability (CNI) score from the sequencing of circulating cell-free tumor DNA (cfDNA), which can be used in the prognosis, diagnosis and monitoring of therapeutic response to cancer. Chronix TheraSure™ Transplant Monitor quantifies the amount of graft derived cell-free DNA in organ recipients to detect early rejection of organ transplants and better assess the transplant health. Chronix Biomedical has operations in the U.S. & Germany, and the commercial launch of their products began in the EU in 2018. TheraSure is a trademark of Chronix Biomedical Inc.


About Oncocyte Corporation

Oncocyte is a molecular diagnostics company whose mission is to provide actionable answers at critical decision points across the cancer care continuum. The Company, through its proprietary tests and pharmaceutical services business, aims to help save lives and improve outcomes by accelerating and optimizing the diagnosis and treatment of cancer. The Company’s tests and services present multiple opportunities to advance cancer care while also driving revenue growth for the Company. Oncocyte recently launched DetermaRx™, a test that identifies early-stage lung cancer patients who are at high risk for cancer recurrence post-resection and predicts benefit from adjuvant chemotherapy. Oncocyte has also launched DetermaIO™, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies, as a research use only tool for pharmaceutical and academic clinical trials. To complement DetermaIO, the company anticipates launching DetermaTx™, a test to assess mutational status of a tumor to help identify the appropriate targeted therapy, in the second half of 2021. The Company also continues with the development of DetermaMx™ as the company seeks to expand into the blood-based monitoring market. Oncocyte’s pharmaceutical services provide pharmaceutical companies who are developing new cancer treatments a full suite of molecular testing services to support the drug development process. DetermaRx, DetermaIO, DetermaMx and DetermaTx are trademarks of Oncocyte Corporation.


About Boustead Securities, LLC

Boustead Securities, LLC (“Boustead”) is an investment banking firm that executes and advises on IPOs, mergers and acquisitions, capital raises and restructuring assignments in a wide array of industries, geographies and transactions, for a broad client base. Boustead’s core value proposition is the ability to create opportunity through innovative solutions and tenacious execution. With experienced professionals in the United States, Boustead’s team moves quickly and provides a broad spectrum of sophisticated financial advice and services. Boustead is a majority owned subsidiary of Boustead & Company Limited, a diversified non-bank financial institution. For more information, please visit www.boustead1828.com


Form CRS/Reg BI Disclaimer:

Boustead Securities, LLC, Sutter Securities Inc., and Sutter Securities Clearing,LLC (SSC) are registered with the Securities and Exchange Commission (SEC) as broker-dealers and are members of the Financial Industry Regulatory Authority (FINRA) and the Securities Investor Protection Corporation (SIPC). Brokerage and investment advisory services and fees differ and it is important for you to understand these differences. Free and simple tools are available to research firms and financial professionals at Investor.gov/CRS, which also provides educational materials about broker-dealers, investment advisers, and investing. When we provide you with a recommendation, we have to act in your best interest and not put our interest ahead of yours. At the same time, the way we make money creates a conflict with your interests. Please strive to understand and ask us about these conflicts because they can affect the recommendations we provide you. There are many risks involved with investing. For Boustead Securities customers and clients, please see our Regulation Best Interest Relationship Guide on the Form CRS Reg BI page on our website at https://www.boustead1828.com/form-crs-reg-bi. For Sutter Securities’ and Sutter Securities Clearing’s customers and clients, please see the Form CRS on the website at https://suttersecurities.com/wp-content/uploads/2020/12/Sutter-Form-CRS-combined-121020.pdf. For FlashFunders’ visitors, you may review the Form CRS of Boustead Securities, Sutter Securities and Sutter Securities Clearing under the Form CRS section. Please also carefully review and verify the accuracy of the information you provide us on account applications, subscription documents and others.


Cautionary Statement Concerning Forward-Looking Statements

This document contains forward-looking statements. In addition, from time to time, we or our representatives may make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our growth in revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as “may,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential,” or “hopes” or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of the Company; our ability to keep pace with new technology and changing market needs; and the competitive environment of our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this document and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties and assumptions about us. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this document and other statements made from time to time by us or our representatives might not occur.

By: Robert Rubin, Senior Managing Director, Boustead Securities

Recently, the Small Business Administration (“SBA”) published 220 pages of new rules on a broad range of topics including regulations regarding small business recertification, joint ventures and Mentor/Protégé programs.


Some of these changes are aimed at streamlining and/or clarifying processes and regulations, for instance, approval of 8(a) JV’s prior to contract award, consistency of NAICS codes for task orders, and consideration of subcontractor capabilities in contract awards.


Impact on Small Business


Some provisions of this document could have a profound impact on the growth and M&A prospects valuation for small businesses – neither of which I believe would be positive. The provisions of the most concern include:

  • Between submission of a proposal and the contract award, a small business must re-certify its size status to the Contracting Officer if it loses its size status due to a M&A transaction.

The offeror may be ineligible for a set-aside contract if a M&A transaction occurs within 180 days of the initial submission of a proposal.

  • Although the SBA has been tightening regulations regarding Small Business Set Aside awards, in the past, many M&A transactions were completed in anticipation of the buyer being able to continue performing under a small business award after a M&A transaction, and, upon contract expiration using that performance to rebid on a full and open basis.

  • In addition, under these new regulations, as they near size standards, small businesses will likely no longer be able to expand their pipeline of future business with additional set aside contracts – negatively impacting future organic growth prospects.


Growth Potential


Limiting the future organic growth potential of a small business and the ability of an acquirer to perform under small business contract awards of a target is a toxic mix which may translate into lower enterprise value for small businesses.


If you would like to discuss how these changes may impact your company please contact Robert N. Rubin:robert.rubin@boustead1828.com | (301) 537-8221


The opinions herein are of the individual and not necessarily of Boustead Securities, LLC or Trident Advisors. There is no guarantee that any specific outcome will be achieved.

 

About Robert N. Rubin


Robert Rubin joined Boustead as Senior Managing Director in 2020 and has over 35 years of experience in Mergers and Acquisitions, the last 25 of which have been specifically focused on the technical services marketplace including Aerospace, Defense and Government contracting in the Washington DC Metropolitan area.

In addition to his background in M&A, he has extensive experience in corporate finance and development with public and privately held companies. He has been involved in more than 40 transactions worldwide, and served as President of the National Capital Chapter and on the International Board of Directors for ACG. Robert is a FINRA registered representative and holds series 7, 24, 63, 79 and 99 licenses.


For more information on M&A's contact:

Robert Rubin

Senior Managing Director

(301) 537-8221

 

About Boustead Securities, LLC

Boustead Securities, LLC (“Boustead”) is an investment banking firm that executes and advises on IPOs, mergers and acquisitions, capital raises and restructuring assignments in a wide array of industries, geographies and transactions, for a broad client base. Boustead’s core value proposition is the ability to create opportunity through innovative solutions and tenacious execution. With experienced professionals in the United States, Boustead’s team moves quickly and provides a broad spectrum of sophisticated financial advice and services. Boustead is a majority owned subsidiary of Boustead & Company Limited, a diversified non-bank financial institution. For more information, please visit www.boustead1828.com.


Forward-Looking Statements

This document contains forward-looking statements. In addition, from time to time, we or our representatives may make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our growth in revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as “may,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential,” or “hopes” or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of the Company; our ability to keep pace with new technology and changing market needs; and the competitive environment of our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this document and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties and assumptions about us. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this document and other statements made from time to time by us or our representatives might not occur.

bottom of page